NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said yesterday that it has completed its previously announced underwritten public offering.

The company sold approximately 13.9 million shares of its common stock at a price to the public of $2.90 per share, including about 1.8 million shares pursuant to the exercise in full of the underwriters' option to purchase additional shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.